Fig. 5.
Fig. 5. IFN-γ lymphocyte content in a patient with AA with hematogic response to treatment, relapse, and retreatment. / This patient had severe AA at presentation, at which time lymphocyte staining was positive for IFN γ. He was treated with ATG/CSA; a hematologic response was observed within 4 months of treatment, when PB lymphocyte staining was negative for IFN γ. The patient experienced a relapse at 14 months and lymphocyte staining was again positive for IFN γ; the CSA dose was increased. The patient subsequently had a second response, and lymphocyte staining became negative for IFN γ. ARC (dotted line) and platelet counts (solid line); inserts show examples of scattergrams of CD8 lymphocytes stained with IFN-γ–FITC mAb at varying times during the clinical course.

IFN-γ lymphocyte content in a patient with AA with hematogic response to treatment, relapse, and retreatment.

This patient had severe AA at presentation, at which time lymphocyte staining was positive for IFN γ. He was treated with ATG/CSA; a hematologic response was observed within 4 months of treatment, when PB lymphocyte staining was negative for IFN γ. The patient experienced a relapse at 14 months and lymphocyte staining was again positive for IFN γ; the CSA dose was increased. The patient subsequently had a second response, and lymphocyte staining became negative for IFN γ. ARC (dotted line) and platelet counts (solid line); inserts show examples of scattergrams of CD8 lymphocytes stained with IFN-γ–FITC mAb at varying times during the clinical course.

Close Modal

or Create an Account

Close Modal
Close Modal